UCLA researchers have described a new form of irritable bowel syndrome that occurs after an acute bout of diverticulitis, a finding that may help lead to better management of symptoms and relief for patients.
The discovery of this new condition, called post-diverticulitis irritable bowel syndrome (PDV–IBS), validates the irritable bowel symptoms that many patients report long after suffering a bout of diverticulitis but that many physicians have waved off as being part of the original condition, said Dr. Brennan Spiegel, an associate professor of medicine at the David Geffen School of Medicine at UCLA and senior author of the research.
"We've known for a long time that after some people develop diverticulitis, they're a different person. They experience recurrent abdominal pains, cramping and diarrhea that they didn't have before," Spiegel said. "The prevailing wisdom has been that once diverticulitis is treated, it's gone. But we've shown that IBS symptoms occur after the diverticulitis, and they may result from an inflammatory process, like a bomb going off in the body and leaving residual damage."
The research was published Sept. 5 in the peer-reviewed journal Clinical Gastroenterology and Hepatology.
As they age, most people develop diverticulosis, or pouches in the lining of the colon. More than 50 percent of people over 60 have the condition, but the pouches usually don't cause any problems. Occasionally, the pouches become inflamed, leading to diverticulitis, which causes pain and infection in the abdomen. Doctors usually treat it with antibiotics, or in more severe cases with surgery.
"A major surprise in our study was that diverticulitis patients not only developed IBS at a higher rate than the controls, but they also developed mood disorders like depression and anxiety at a higher rate," Spiegel said. "Because IBS and mood disorders often go hand in hand, this suggests that acute diverticulitis might even set off a process leading to long-standing changes in the brain–gut axis."
The discovery of PDV–IBS could mean better attention to patients complaining of symptoms after diverticulitis, symptoms that up until now may have been dismissed by physicians. 
"Patients often report ongoing IBS symptoms after the diverticulitis has long passed, and this study supports their beliefs and introduces a new diagnosis," Spiegel said. "If doctors recognize this, they may take the symptoms more seriously and manage them actively, just as they can manage IBS actively with various new drugs on the market and currently in development."
More than 1,000 patient records from the West Los Angeles Veteran's Affairs Medical Center were examined for the two-year study, including those of patients who had suffered acute diverticulitis and those of another group of patients who had not. The groups were matched for age and sex and had similar co-morbidities — other existing health problems. The groups were followed for many years as UCLA researchers tracked the differences in IBS diagnoses and mood disorders.
"This study expands our understanding a little bit about what might cause IBS," Spiegel said. "It's such a common condition, and there may be different flavors. We've now added a new flavor to the menu — a new risk factor for developing IBS. By learning more, we might be able to expand the therapies we can use on these patients."
The study was funded by Shire Pharmaceuticals.
"Our findings support the evolving paradigm of diverticular disease as a chronic illness — not merely an acute condition marked by abrupt complications. Far from a self-limited episode, acute diverticulitis may become a chronic disorder in some patients," the study states. "Diverticulitis is correlated with not only chronic IBS symptoms, but also long-term emotional distress beyond the event itself. Awareness of this possible risk is important because persistent, untreated gastrointestinal symptoms and comorbid depression may worsen outcome and increase the economic burden of an already prevalent disease."
For more news, visit the UCLA Newsroom and follow us on Twitter.